Company Profile

With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.


Shandong Linuo Pharmaceutical Co., Ltd. was established in 2002. It is a wholly-owned subsidiary of Shandong Keyuan Pharmaceutical Co., Ltd. (stock code 301281.SZ), with a modern, high-tech and new chemical drug manufacturing facilities integrating R&D, production and sales. There’re 21 patent authorizations, as well as honorary titles such as high-tech enterprises, enterprises with the most growth potential in China's pharmaceutical industry, and small and medium-sized enterprises in Shandong Province.

2002 Year

The company was founded in 2002.

170 million yuan

The company's registered capital is 170 million yuan.

Shandong LINUO Pharmaceutical Co., Ltd


The company has advanced tablet, capsule, paste and spray production lines and supporting facilities. The annual output of tablets and capsules can reach 1.1 billion pieces (grains), 5 million ointments, and 5 million bottles of sprays. Passed the new national GMP certification. The company currently has 40 drug production approval documents, of which 29 drugs are included in the national medical insurance list, 18 drugs are included in the national essential drug list, Fluoxetine Hydrochloride Dispersible Tablets, Isosorbide Mononitrate Tablets, and Isosorbide Mononitrate Sustained-Release Tablets, etc. have passed the national generic drug consistency evaluation, and are products in the national drug collection catalog. Isosorbide Mononitrate Tablets have won the bid for the seventh batch of national centralized procurement in 2022. Fluoxetine Hydrochloride Dispersible Tablets has won provincial-level centralized procurement renewal bids in 11 provinces including Jiangsu, Hebei, and Liaoning.

The company has built a marketing service system covering the whole country, has a high-quality, professional marketing and academic promotion team, and maintains long-term and stable strategic cooperative relations with major domestic medical institutions and large pharmaceutical distribution business groups.


The raw materials of the company's main products are all from the parent company Keyuan Pharmaceutical (stock code 301281.SZ). Keyuan Pharmaceutical is a leading enterprise in the subdivision of raw material drugs in China. Its products cover key disease areas such as hypoglycemic, anesthesia, cardiovascular and mental diseases. It has successively obtained EU EDQM, US FDA, Japanese PMDA, and Korean KFDA certifications and other official certifications of many other countries, which have provided Linuo Pharmaceutical with stable and high-quality raw material support, and enhance the market competitiveness.

Linuo Pharmaceutical is committed to becoming a first-class chemical pharmaceutical manufacturing enterprise in China, integrating the new generation of information technology and advanced manufacturing technology, building an intelligent chemical factory with high efficiency, energy saving, green and environmental protection, and realizing the intelligentization, digitalization and technologicalization of the whole production process.

Shandong LINUO Pharmaceutical Co., Ltd
Shandong LINUO Pharmaceutical Co., Ltd


Linuo Pharmaceutical attaches great importance to the research and development and innovation of drugs, and the proportion of research and development investment continues to exceed 15%, increasing innovation. Established a research institute, set up a research and development team with reasonable academic qualifications and professional disciplines, and carried out independent research and development of drugs; vigorously introduced advanced technologies at home and abroad, and established extensive production and research cooperation with many well-known universities and research institutes at home and abroad. In the future, relying on the excellent scientific research resources of various universities, we will establish a new drug research and development platform, improve the cultivation of talent echelon, and realize the industrialization transfer of research results; adhere to the combination of independent research and development and outsourcing research and development, and cooperate with well-known domestic CRO and CDMO Establish cooperative relations with enterprises, including WuXi AppTec, Pharmaron, Beijing Nuokangda, Beijing Sunshine Nuovo, etc., extensively carry out cooperation and exchanges in the research and development of generic drugs and innovative drugs, improve the R&D business chain, improve R&D efficiency, and improve return on investment.

In the future, Linuo Pharmaceutical will continue to give full play to the synergistic advantages of the integration of raw materials and preparations, take technology research and development as the guide, and promote product upgrades; take strict quality management as the cornerstone to build the lifeline of enterprise development; support the nationwide marketing network, Let high-quality drugs benefit more patients, expand and strengthen brand awareness and influence, and strive to practice the enterprise spirit of "serving the country with industry, pursuing excellence, serving the society, and benefiting mankind".